Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Public ClinicalTrials.gov record NCT06906341. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)
Study identification
- NCT ID
- NCT06906341
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Corcept Therapeutics
- Industry
- Enrollment
- 270 participants
Conditions and interventions
Interventions
- Bevacizumab 10 mg/kg Drug
- Nab-paclitaxel 80 mg/m^2 Drug
- Relacorilant 150 mg once daily (QD) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2025
- Primary completion
- Jul 31, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Apr 13, 2026
2025 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 004 | Birmingham | Alabama | 35233 | Recruiting |
| 150 | Palo Alto | California | 94304 | Recruiting |
| 014 | San Francisco | California | 94143 | Recruiting |
| 544 | Fort Myers | Florida | 33901 | Recruiting |
| 335 | Miami Beach | Florida | 33140 | Recruiting |
| 543 | West Palm Beach | Florida | 33041 | Recruiting |
| 518 | Minneapolis | Minnesota | 55404 | Recruiting |
| 334 | Kansas City | Missouri | 64132 | Recruiting |
| 521 | St Louis | Missouri | 63110 | Recruiting |
| 292 | Albuquerque | New Mexico | 97102 | Recruiting |
| 304 | Centerville | Ohio | 45459 | Recruiting |
| 517 | Eugene | Oregon | 97401 | Recruiting |
| 127 | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| 522 | Fairfax | Virginia | 22031 | Recruiting |
| 300 | Norfolk | Virginia | 23502 | Recruiting |
| 121 | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06906341, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06906341 live on ClinicalTrials.gov.